Korea Investment CORP Makes New Investment in IQVIA Holdings Inc. $IQV

Korea Investment CORP purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 72,030 shares of the medical research company’s stock, valued at approximately $13,918,000.

A number of other hedge funds have also recently made changes to their positions in the stock. Apella Capital LLC lifted its stake in IQVIA by 5.1% during the first quarter. Apella Capital LLC now owns 1,196 shares of the medical research company’s stock worth $211,000 after purchasing an additional 58 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of IQVIA by 1.3% in the fourth quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after buying an additional 60 shares in the last quarter. Private Advisor Group LLC raised its holdings in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 63 shares during the period. Breakwater Capital Group lifted its stake in IQVIA by 3.2% during the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock worth $401,000 after acquiring an additional 64 shares in the last quarter. Finally, Keybank National Association OH boosted its holdings in IQVIA by 0.7% during the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after acquiring an additional 67 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on IQV. TD Cowen boosted their price target on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Robert W. Baird upped their target price on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Morgan Stanley restated an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Stock Up 0.1%

Shares of NYSE IQV opened at $260.17 on Monday. The business has a 50-day moving average of $213.32 and a two-hundred day moving average of $187.21. The company has a market capitalization of $42.82 billion, a price-to-earnings ratio of 32.28, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $260.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Activity at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider owned 1,348 shares in the company, valued at $317,143.96. This represents a 57.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 12,913 shares of company stock worth $3,098,793 in the last ninety days. Company insiders own 1.70% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.